Close Menu

NEW YORK – PerkinElmer said after the close of the market on Thursday it is offering $800 million in senior notes.

The Waltham, Massachusetts-based firm is offering $400 million aggregate principal amount of 2.550 percent senior notes due 2031 at an issue price of 99.965 percent of the principal amount and $400 million aggregate principal of 3.625 percent senior notes due 2051 at an issue price of 99.999 percent of the principal amount.

The notes will pay on a semi-annual basis, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.